OverweightNCT07627074
Weight Loss in Adults Using Semaglutide (Real-world Study)
An observational study of Overweight and Obesity, run by Novo Nordisk A/S at 2 sites in 2 countries.
Trial summary
The purpose of the study is to assess the weight loss in participants treated with commercially available semaglutide according to routine clinical practice at the discretion of the treating physician. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Overweight, Obesity
- What is being tested?
- Semaglutide
- How many people
- 237,211 participants
- Where
- 2 sitesin 2 countries
- Study dates
- 12 May 2026to 15 Jun 2026
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: The study population comprises adults initiating semaglutide in routine clinical practice.
Who may be able to join
- Initiation of semaglutide for weight management during the study period.
- Age more than or equal to (≥) 18 at treatment initiation
- Baseline body mass index (BMI) ≥27 and less than (<) 30 kilogram per meter square (kg/m^2) with at least one weight-related comorbidity, or BMI ≥30 kg/m^2.
- Other inclusion criteria as defined in the protocol are applicable.
Who cannot join
- Prior use of glucagon-like peptide-1 receptor agonist (GLP-1 RA) based medication or other obesity management medication (OMMs).
- Bariatric surgery at baseline.
- Diabetes at baseline.
- Pregnancy at baseline.
Trial locations and contacts
2 sites in 2 countries.
2 sites in 2 countries
United States1 site
Novo Nordisk Investigational Site
Seattle, Washington, 98039
About this study
Official title: Real-world Weight Outcomes in Adults Treated With Semaglutide s.c. 1.0 mg or 1.7 mg for Weight Management: a Non-interventional Cohort Study
The purpose of the study is to assess the weight loss in participants treated with commercially available semaglutide according to routine clinical practice at the discretion of the treating physician.
- Conditions
- Overweight, Obesity
- Being tested
- Semaglutide
- Medical subject headings
- Overweight, Obesity
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
SemaglutideDrug
This is a retrospective, non-interventional study; therefore, no intervention was administered as part of the study.
| Study group | Role | What they receive |
|---|---|---|
| Semaglutide | Adults initiating semaglutide in routine clinical care and assigned to 0.5, 1.0, 1.7 or 2.4 mg at approximately Week 20. Participants are followed from treatment initiation up to 68 weeks using data collected during routine clinical practice. No study-specific interventions, visits, or procedures are performed. Data are derived from secondary use of routinely collected healthcare data. Receives: Drug: Semaglutide |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in body weight
Measured as kilogram (kg)
Measured: From index date (day 0) to week 68 (day 476)
Change in body weight
Measured as percentage (%)
Measured: From index date (day 0) to week 68 (day 476)
Proportion of individuals achieving a clinically meaningful weight loss
Binary (yes/no): estimated ≥5% reduction from baseline body weight
Measured: From index date (day 0) to week 68 (day 476)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 Jun 2026
- Study start12 May 2026
- Primary completion15 Jun 2026
- Study completion15 Jun 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for OverweightStudies of the same condition, open and under way.
- More trials run by Novo Nordisk A/SThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 237,211 participants (actual)
Sponsor and investigators
- Lead sponsor
- Novo Nordisk A/S
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Clinical Transparency (dept. 2834), Study director, Novo Nordisk A/S
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07627074
- Sponsor's protocol ID
- NN9536-8874
- Other IDs
- U1111-1338-2016
- Status last verified
- Sep 2026
- First submitted
- 30 May 2026
- Last updated
- 4 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Study at a glance
From the registry record, last updated by the sponsor on 4 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Real-world Weight Outcomes in Adults Treated With Semaglutide s.c. 1.0 mg or 1.7 mg for Weight Management: a Non-interventional Cohort Study
- ClinicalTrials.gov ID
- NCT07627074
- Acronym / sponsor ID
- NN9536-8874
- Conditions
- Overweight, Obesity
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 237,211 participants (actual)
- Lead sponsor
- Novo Nordisk A/SIndustry (pharma, biotech, devices)
- Study start
- 12 May 2026 (actual)
- Primary completion
- 15 Jun 2026 (actual)
- Study completion
- 15 Jun 2026 (actual)
- First posted
- 4 Jun 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of the study is to assess the weight loss in participants treated with commercially available semaglutide according to routine clinical practice at the discretion of the treating physician.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Semaglutide | – | Drug: SemaglutideAdults initiating semaglutide in routine clinical care and assigned to 0.5, 1.0, 1.7 or 2.4 mg at approximately Week 20. Participants are followed from treatment initiation up to 68 weeks using data collected during routine clinical practice. No study-specific interventions, visits, or procedures are performed. Data are derived from secondary use of routinely collected healthcare data. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- The study population comprises adults initiating semaglutide in routine clinical practice.
Key inclusion criteria (4 listed)
- Initiation of semaglutide for weight management during the study period.
- Age more than or equal to (≥) 18 at treatment initiation
- Baseline body mass index (BMI) ≥27 and less than (<) 30 kilogram per meter square (kg/m^2) with at least one weight-related comorbidity, or BMI ≥30 kg/m^2.
- Other inclusion criteria as defined in the protocol are applicable.
Key exclusion criteria (4 listed)
- Prior use of glucagon-like peptide-1 receptor agonist (GLP-1 RA) based medication or other obesity management medication (OMMs).
- Bariatric surgery at baseline.
- Diabetes at baseline.
- Pregnancy at baseline.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| SemaglutideThis is a retrospective, non-interventional study; therefore, no intervention was administered as part of the study. | Drug | Semaglutide |
Primary outcome
Change in body weight
Time frame: From index date (day 0) to week 68 (day 476)
Measured as kilogram (kg)
Change in body weight
Time frame: From index date (day 0) to week 68 (day 476)
Measured as percentage (%)
Proportion of individuals achieving a clinically meaningful weight loss
Time frame: From index date (day 0) to week 68 (day 476)
Binary (yes/no): estimated ≥5% reduction from baseline body weight
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 Sep 2026.
- Individual participant dataSharing planned: Yes. According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Related trials for Overweight
Not yet recruiting
Transcutaneous Auricular Vagus Nerve Stimulation Combined With Lifestyle Intervention for Visceral Fat Reduction in Adults With Overweight or Obesity
Overweight, Obesity
Not yet recruitingObservational study
Assessing the Impact of Perceptions of Unpredictability on Objective Measures of Food Consumption and Metabolism
Healthy Volunteer, Obestity
RecruitingPhase 1/2
HS235 Study in Overweight and Obese Participants With Combined Pre and Post-Capillary Pulmonary Hypertension Due to Heart Failure With Preserved Ejection Fraction
Pulmonary Hypertension, Heart Failure With Preserved Ejection Fraction
Not yet recruitingPhase 3
ELEVATE-LIVER: A Study to Test Whether Survodutide Helps Improve Heart Structure and Function in People With Overweight or Obesity and Fatty Liver Disease
Obesity, Metabolic Dysfunction-associated Steatotic Liver Disease
Not yet recruitingObservational study
A Natural History of Genetic and Environmental Predictors of Pubertal Timing Among Youth With Obesity
Obesity
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Clinical Transparency (dept. 2834) study director
Novo Nordisk A/S
2 sites in 2 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Overweight and Obesity, run by Novo Nordisk A/S at 2 sites in 2 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 4 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in United States, United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in body weight (time frame: From index date (day 0) to week 68 (day 476)). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Sep 2026.